Form 4: Apimeds Pharmaceuticals Director Jakap Koo Reports Stock Purchase

Director Jakap Koo reports purchasing 28,500 shares of Apimeds Pharmaceuticals US, Inc. at an average price of $1.99 per share.

Summary

• On May 12, 2025, Jakap Koo, a director of Apimeds Pharmaceuticals US, Inc., purchased 28,500 shares of common stock at a weighted average price of $1.99 per share.
• The shares were bought in multiple transactions with prices ranging from $1.9774 to $2.2000.
• Following the transaction, Koo directly owns 643,885 shares of Apimeds Pharmaceuticals US, Inc.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock purchase by a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, buys or sells shares of their company's stock. It provides transparency to the market regarding the transactions of company insiders.

Stakeholder Impact

• The transaction provides information to shareholders regarding the actions of a company insider.

Key Dates

Keywords

Apimeds Pharmaceuticals, Jakap Koo, Director, Stock Purchase, Form 4, Beneficial Ownership, Securities